These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3144530)

  • 1. Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
    Hof H; Fabrig J
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():123-7. PubMed ID: 3144530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of experimental Salmonella typhimurium infection in mice with fleroxacin.
    Butler T; Jacobs MR; Farhi D
    Antimicrob Agents Chemother; 1988 May; 32(5):791-2. PubMed ID: 3134853
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB; Chu DT; Bower RR; Jarvis KP; Ramer NR; Shipkowitz N
    Antimicrob Agents Chemother; 1986 Feb; 29(2):201-8. PubMed ID: 3521473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of method, medium, pH and inoculum on the in-vitro antibacterial activities of fleroxacin and norfloxacin.
    Hohl P; Felber AM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():71-80. PubMed ID: 3144552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
    Paganoni R; Herzog C; Braunsteiner A; Hohl P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():3-17. PubMed ID: 3144545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of fleroxacin against experimental pneumonia in mice.
    Niki Y; Watanabe M; Tasaka Y; Umeki S; Soejima R
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():129-31. PubMed ID: 3144531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin].
    Lecleire S; Di Fiore F; Hervé S; Goria O; Savoye G; Colin R; Lerebours E
    Presse Med; 2003 Mar; 32(12):550-2. PubMed ID: 12714922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of fleroxacin.
    Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of sparfloxacin against experimental renal infections in mice.
    Georgopoulos A; Feistauer SM; Graninger W; Pfleger S; Georgopoulos M
    Antimicrob Agents Chemother; 1992 Feb; 36(2):505-7. PubMed ID: 1318685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():35-41. PubMed ID: 3144547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
    Ortiz J; Vila MC; Soriano G; Miñana J; Gana J; Mirelis B; Novella MT; Coll S; Sábat M; Andreu M; Prats G; Solá R; Guarner C
    Hepatology; 1999 Apr; 29(4):1064-9. PubMed ID: 10094947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of fleroxacin against aerobic gram-positive bacteria including Corynebacterium jeikeium.
    Hohl P; Felber AM
    Chemotherapy; 1990; 36(6):403-6. PubMed ID: 2127242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinafloxacin (CL 960) is superior to standard therapeutics in the treatment of murine listeriosis and salmonellosis.
    Nichterlein T; Bornitz F; Kretschmar M; Hof H
    Zentralbl Bakteriol; 1997 Oct; 286(3):401-12. PubMed ID: 9361386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between growth curves and killing curves of Escherichia coli in the presence of fleroxacin and ampicillin.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1989; 35(6):423-30. PubMed ID: 2515040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative efficacy of ampicillin, chloramphenicol, cefotaxime, ceftriaxone and pefloxacin in experimental Salmonella typhimurium infection].
    Nauciel C; Martin E
    Pathol Biol (Paris); 1987 Nov; 35(9):1239-42. PubMed ID: 3320900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.